Trial

NCT00796861

Trial of Sunitinib for Refractory Malignant Ascites
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Milton S. Hershey Medical Center
Collaborators
Condition
Ascites
Intervention
Sunitinib
Why stopped
Phycisican decided to terminate study due to slow patient accrual.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-12-20